Business Context and Reporting Period
This Form 8-K was filed by Amedica Corporation (not Sintx Technologies, Inc.) on November 26, 2014. The report details the closing of a previously announced firm commitment underwritten public offering of units.
Key Financial Metrics
- Gross Proceeds: Approximately $13.0 million (before underwriting discounts, commissions, and estimated expenses).
- Units Issued: 11,441,646 units at a public price of $1.14 per unit.
- Unit Composition: Each unit consists of one share of common stock and one warrant to purchase one share of common stock.
- Additional Warrants: 1,716,246 warrants issued pursuant to the partial exercise of the underwriters' over-allotment option.
- Warrant Terms: Exercise price of $1.48 per share; exercisable on a cashless basis; expire five years from issuance.
- Underwriter: Dawson James Securities, Inc. (sole book-running manager).
Material Changes
The primary material change is the successful closing of the equity offering, resulting in an immediate increase in the company's cash position (gross proceeds) and an expansion of its outstanding share and warrant count. The filing references a prior pricing announcement on November 21, 2014.
Outlook and Risks
The filing confirms the effectiveness of the registration statement (Form S-1, File No. 333-199753) on November 20, 2014. It includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful. No specific forward-looking guidance or management commentary regarding future operations is provided in this specific text.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and commissions, as only gross proceeds ($13.0 million) are stated.
- Confirm the exact dilution impact on existing shareholders given the issuance of 11.4 million units plus 1.7 million additional warrants.
- Review the full prospectus (available via Dawson James Securities) for detailed use of proceeds and risk factors.
- Check subsequent filings for the actual cash balance impact and any changes in the company's capital structure.